News Quantified

NGM – ngm biopharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

NGM Bio Announces Closing of Tender Offer [Yahoo! Finance]

NGM Bio Announces Closing of Tender Offer

Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm

0.0%

BEAT

5.1%

BEAT

-0.4%

IN-LINE

Form 25-NSE NGM BIOPHARMACEUTICALS Filed by: Nasdaq Stock Market LLC

Form SC 13D/A NGM BIOPHARMACEUTICALS Filed by: COLUMN GROUP L P

Form S-8 POS NGM BIOPHARMACEUTICALS

Form S-8 POS NGM BIOPHARMACEUTICALS

Form S-8 POS NGM BIOPHARMACEUTICALS

Top News Gainers

2/23 NGM Bio to Host Conference Call to Discuss Preliminary Topline Results, Including Histology Data, from 24-Week Phase 2 Study of Aldafermin in Patients with NASH 16.6%

3/19 NGM Biopharmaceuticals (NYSE: NGM) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $30.00 price target on the stock. 15.7%

3/23 Form 4 NGM BIOPHARMACEUTICALS For: Mar 19 Filed by: Svennilson Peter 11.0%

8/12 NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results 10.6%

11/13 Form 4 NGM BIOPHARMACEUTICALS For: Nov 11 Filed by: Svennilson Peter 9.3%

4/2 Form SC 13D/A NGM BIOPHARMACEUTICALS Filed by: COLUMN GROUP L P 6.8%

4/7 Form 4 NGM BIOPHARMACEUTICALS For: Apr 03 Filed by: COLUMN GROUP II, LP 5.9%

5/16 NGM Bio Reports Recent Highlights and First Quarter 2019 Financial Results 5.9%

10/16 Form 4 NGM BIOPHARMACEUTICALS For: Oct 14 Filed by: PONOI CAPITAL, LP 5.7%

4/6 NGM Biopharmaceuticals (NYSE: NGM) is now covered by analysts at Raymond James. They set a "strong-buy" rating on the stock. 5.6%

Top News Decliners

10/7 NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH -23.0%

3/17 Form S-8 NGM BIOPHARMACEUTICALS -15.8%

2/25 NGM Biopharmaceuticals (NYSE: NGM) had its price target raised by analysts at Stifel Nicolaus from $26.00 to $33.00. They now have a "buy" rating on the stock. -11.5%

3/9 Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company -8.7%

11/12 Form 10-Q NGM BIOPHARMACEUTICALS For: Sep 30 -7.4%

2/5 NGM Biopharmaceuticals (NYSE: NGM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -6.8%

3/27 NGM Biopharmaceuticals (NYSE: NGM) had its price target lowered by analysts at Citigroup Inc from $34.00 to $28.00. They now have a "buy" rating on the stock. -6.6%

4/14 Form 3 NGM BIOPHARMACEUTICALS For: Mar 11 Filed by: Lieu Hsiao D -5.9%

11/17 NGM Biopharmaceuticals, Inc. Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance News] -4.7%

12/5 NGM Biopharmaceuticals (NYSE: NGM) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $26.00 price target on the stock. -4.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day